1️⃣ FDA tries to make repurposing investable FDA opened a new push for drug repurposing, asking industry where approved medicines could be redirected into unmet needs and how evidence should be judged.
💡 Why it matters If FDA makes this practical, old assets get a clearer regulatory path and cheaper clinical optionality.
☕ Coffee talk Who wants to underwrite the trial when the molecule is already off-patent?
2️⃣ NICE moves SMA drugs into routine NHS access NICE recommended routine NHS access for nusinersen and risdiplam after managed-access data changed the reimbursement answer in spinal muscular atrophy.
💡 Why it matters That is a useful proof point for outcomes-based access when launch evidence is thin but the budget impact is real.
☕ Coffee talk How many rare-disease files now need a managed-access plan before pricing even starts?
3️⃣ FDA gives BeOne a hematology foothold FDA granted accelerated approval to BeOne’s BTK inhibitor sonrotoclax for relapsed or refractory mantle cell lymphoma after at least two prior lines of therapy.
💡 Why it matters China-origin oncology assets are no longer just licensing inventory. Some are becoming direct US regulatory competitors.
☕ Coffee talk If the label is narrow today, which incumbent is quietly checking the combo data?